Profound Medical (PROF)
(Delayed Data from NSDQ)
$5.58 USD
-0.11 (-1.94%)
Updated Aug 5, 2025 03:59 PM ET
After-Market: $5.41 -0.17 (-3.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROF 5.58 -0.11(-1.94%)
Will PROF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROF
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
Other News for PROF
Profound Medical to Release Second Quarter 2025 Financial Results on August 14 -- Conference ...
Profound Medical (PROF) Shares Cross Above 200 DMA
Profound Medical (PROF) Advances BPH Treatment with New Module | PROF Stock News
Profound Medical announces first commercial BPH treatment using TULSA-AI
Profound Medical announces first commercial BPH treatment using TULSA-AI